NR4A1 and breast carcinoma: Biomarker-driven clinical trials evaluate targeted therapies and combination regimens in specific subgroups of HER2-positive breast cancer patients, such as those with HER2 mutations or amplifications, hormone receptor positivity, or specific genomic alterations.